I hold another stock other than PMCB. Their CEO was smart enough to draw up a poison pill. Also to get the valuation of the company prior to the poison pill be drawn up. That was back in 2013 so I am sure the valuation could be more.
Just hope Pharmacyte can stave off potential hostiles until after their technology shows proof of concept and is out on the market.
One more thing I will interject here that I have brought in before. E I Lily was able to broker their "gold standard" drug into $10 billion (yes with a B as in billion $$). That one only extended lives out 6-8 months.
Celgene's drug was able to extend lives out past 8 months. No information as to what kind of money Celgene was able to get for their drug.
Lohr's original phase 2b went past 11 months. This is without the tweaking Von Hoff was involved with. Lohr's study was not fine tuned, and pretty
much a rough draft. The Cell bank used was probably not as robust (just a guess).
$2-$3 dollars would be extremely cheap for this technology. $10 billion dollars for PMCB's gold standard drug would also be doable,
So PMCB has about 1 billion shares outstanding..... not quite, but close. If able to broker this technology into $10 billion as E I Lily did theirs, PMCB is looking at a very big share price with a very conservative PE ratio of 7.
Yeah, I too am hoping management doesn't do something really dumb here, and screw shareholders out of a lot of $$$$$$.
And this ONLY the inoperable pancreatic cancer part of CiaB.
Diabetes will be another potential monster if they ever get their proof of concept to market, but first things first.
News 
Market Data 
Discover 
